Navigation Links
Genmab Announces HuMax-CD32b Pre-Clinical Program
Date:1/4/2008

eams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Files IND for Second Genmab Antibody
2. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
3. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
4. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
5. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
6. Genmab Announces Results for the First Nine Months of 2007
7. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
8. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
9. Genmab A/S - Company Announcement
10. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
11. Genmab Announces Asset Exchange Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... , , ... /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the ... of cancer, today announced the dosing of the first patient under ... Therapy in prostate cancer patients. The study will evaluate the localization, ...
... 11 Allscripts (Nasdaq: MDRX ) announced today ... centers of the mid-South and the flagship of Vanderbilt University Medical ... ensure continuity of care and improve the efficiency of the hospital patient ... , (Logo: ...
... --, -- Revenue increased 26.4% to $26.1 million, ... than 200 basis points to 10.3%; Adjusted diluted EPS increased ... -- Sales of PurCotton(R) products increased 71.1% to $1.9 Million, ... the first six months in fiscal year 2009, ...
Cached Biology Technology:Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 2Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 3Vanderbilt University Hospital Selects Allscripts Care Management 2Vanderbilt University Hospital Selects Allscripts Care Management 3Vanderbilt University Hospital Selects Allscripts Care Management 4Vanderbilt University Hospital Selects Allscripts Care Management 5Vanderbilt University Hospital Selects Allscripts Care Management 6Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 2Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 3Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 4Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 5Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 6Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 7Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 8Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 9Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 10Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 11Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 12Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 13Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 14Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 15Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 16Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 17Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 18Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 19
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/18/2014)... A team of researchers led by a ... selected to receive a $7.5 million Department of Defense ... and basic scientific foundations for the predictable design of ... wide diversity of structures from plants and animals, including ... taking what biological systems have constructed over millions of ...
(Date:4/17/2014)... CHAMPAIGN, Ill. A drug under clinical trials to ... of broad-spectrum drugs that act against various bacteria, fungal ... study by University of Illinois chemists and collaborators. , ... the team determined the different ways the drug SQ109 ... tweaked to target other pathogens from yeast to malaria ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Multitarget TB drug could treat other diseases, evade resistance 2
... celebrates distinguished government scientist Professor Robert (Bob) Watson who ... Chief Scientific Advisor to the Department of Environment, ... alumnus, Professor Watson is recognised for his contributions to ... and global warming. Professor Peter Heathcote, Head of ...
... A Cardiff University researcher has secured a highly sought-after ... stage. Dr Paola Borri, Cardiff School of Biosciences, is ... interface between life and physical sciences Now, she has ... Leadership Award for the next five years. This will support ...
... at Virginia Tech have constructed a mathematical and computational ... simulate the cellular and molecular changes underlying chronic inflammation ... explore different interactions of cells in the immune system, ... the colon, and identify intervention points to perhaps stop ...
Cached Biology News:Honorary Fellowship awarded to government Chief Scientific Advisor 2Boost for world-leading microscopy project 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3
... SBED Protein:Protein Interaction Reagent A powerful ... rapidly gained traction as an in vitro ... number of publications feature the exclusive Pierce ... study a variety of issues relating to ...
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
... MULTI-FUN Incubator is a compact benchtop ... a microprocessor controller with a large ... and agitation speed. Air circulation inside ... incubator. Temperature can be easily calibrated ...
Biology Products: